Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 1, 2001, Pages 69-87

  Singh, B N ^a   Sarma, J S M ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BENZOFURAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DOFETILIDE; DRONEDARONE; ERSENTILIDE; IBUTILIDE; ION CHANNEL; METOPROLOL; QUINIDINE; SOTALOL; SR 33589B; TEDISAMIL; TRECETILIDE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DEVICE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG USE; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART CONDUCTION; HEART PAPILLARY MUSCLE; HEART REPOLARIZATION; HEART VENTRICLE FUNCTION; HUMAN; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SINUS RHYTHM; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034765771     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600108     Document Type: Conference Paper

References (111)

1. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474
2. The effect of amiodarone, a new antianginal drug, on cardiac muscle
3. Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm
4. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility
5. Evolution of diagnostic and interventional cardiac electrophysiology: Historical review
6. Concomitant device and drug therapy: Current trends, potential benefits, and adverse interactions
7. Routine prophylactic lidocaine administration in acute myocardial infarction. An idea whose time is all but gone?
8. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
9. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
10. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985
11. Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. A metaanalysis of randomized control trials
12. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
13. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis
14. A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias
15. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias
16. The Cascade Study - Randomized anti-arrhythmic drug therapy in survivors of cardiac arrest in Seattle
17. Effects of flecainide and quinidine on human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit, and dog tissues
18. An overview of arrhythmias and antiarrhythmic approaches
19. What should we expect from the next generation of antiarrhythinic drugs?
20. Atrial fibrillation following investigation of rhythm management: AFFIRM Study Design
21. The effects of antiarrhythmic therapy in maintaining stability of sinus rhythm in atrial fibrillation
22. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
23. Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone
24. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH)
25. Improved survival with an implantable defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmias
26. Relative effectivenes of the implantable cardioverterdefibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular function who have survived malignant ventricular arrhythmias. Antiarrhythmics versus implantable defibrillators
27. Three-year follow patient randomized in the metoprolol in dilated cardiornyopathy trial
28. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart failure (Merit-HF)
29. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)
30. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial
31. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The Precise Trial
32. Randomized placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
33. Efficacy of prophylaxis of amiodarone on mortality after myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6,500 patients in randomized trials
34. Amiodarone interaction with beta-blockers: Analysis of merged EMIAT and CAMIAT data bases
35. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction
36. Approaches to prevention of sudden death: Need for fundamental reevaluation
37. The idiopathic long QT interval syndrome: Progress and questions
38. A comparison of electrophysiologically guided antiarrhythmic drug therapy with betablocker therapy to patients with symptomatic sustained tachyarrhythmias
39. Beta-blockade during myocardial infarction: An overview of randomized trials
40. The coming of age of the class III antiarrhythmic principle: Retrospective and future trends
41. Importance of beta blockade in the therapy of serious ventricular arrhythmias
42. Evidence-based analysis of amiodarone efficacy and safety
43. A symposium: Controlling cardiac arrhythmias by sotalol, a broad-spectrum antiarrhythmic with beta-blocking effects and class III activity
44. The adrenergic antagonism of amiodarone
45. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors
46. Channel specificity in antiarrhythmic drug action. Mechanism of potassium-channel block and its role in suppressing and aggravating cardiac arrhythmias
47. Two components of cardiac delayed rectifier K+ current: Differential sensitivity to block by class III antiarrhythmic agents
48. Efficacy of safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation
49. Acute conversion of atrial flutter and fibrillation: Direct current cardioversion versus intravenously administered pure class III agents
50. Ibutilide and the treatment of atrial arrhythmias. A new drug - Almost unheralded - Is now available to US physicians
51. Class III antiarrhythmic drugs in atrial fibrillation: Focus on dofetilide
52. Comparative mechanisms of action of antlarrhythmic drugs
53. Maintenance of sinus rhythm with oral d,1-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter
54. Sotalol: Current status and expanding indications
55. Long-term efficacy of amiodarone for the maintenance of sinus rhythm in patients with refractory atrial fibrillation or flutter
56. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery
57. Antiarrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization
58. Amiodarone to prevent recurrence of atrial fibrillation
59. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
60. Amiodarone: The expanding role and how to follow a patient on chronic therapy
61. Amiodarone-associated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia
62. Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle
63. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart
64. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and danger of reverse use dependence
65. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent
66. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III actions
67. Barium-induced non-driven action potentials as a model of triggered potentials from early afterdepolarization: Significance of slow-channel activity and differing effects of quinidine and amiodarone
68. Effects of amiodarone, sematilide, and sotalol on QT dispersion
69. Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death
70. A symposium: Approaches to controlling cardiac arrhythmias: Focus on amiodarone, the last 15 years
71. Prevention of implantable-defibrillator shocks by treatment with sotalol
72. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with hemodynamically destabilizing ventricular tachycardia and fibrillation
73. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias
74. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
75. Cellular electropharmacology of amiodarone
76. Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact
77. The historical development, cellular electrophysiology, and pharmacology of amiodarone
78. The frequency-dependent electrophysiologic effects of amiodarone in humans
79. Amiodarone-associated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia
80. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent
81. Effects of amiodarone on the circadian rhythm and power spectral analysis of heart rate and QT interval: Significance of the control sudden cardiac death
82. Mechanisms underlying variability in response to drug therapy: Implications for amiodarone use
83. Amiodraone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
84. Beneficial effects of low-dose amiodarone in patients with congestive heart failure: A placebo-controlled trial
85. Therapy of susained ventricular arrhythmias with amiodarone: Prediction of efficacy with serial electrophysiologic studies
86. Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary
87. The effects of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors
88. Competition of thyroid hormone action by amiodarone in rat pituitary tumor cells
89. Structure-function relationship of inhibition of the 3,5,3′-triidothyronine binding to the alpha 1 and beta 1-thyroid hormone receptor by amiodarone analogs
90. SR 33589, a new amiodarone-like antiarrhythmic agent
91. SR33589, a new amiodarone-like antiarrhythmic agent: Anti-adrenoceptor activity in anesthetized and conscious dogs
92. SR33589, a new amiodarone-like antiarrhythmic agent: Electrophysiologic effects in anesthetized dogs
93. Electrophysiological and hemodynamic effects of a new amiodarone-like agent following acute and chronic administration in anaesthetized dogs
94. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, d,1-sotalol, and lignocaine on ischemia-induced ventricular arrhythmias in anesthetized pigs
95. SR33589, a new amiodarone-like agent: Effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats
96. Electrophysiological and antifibrillatory actions of a new amiodarone-like agent dronedarone, in experimental atrial fibrillation
97. Electrophysiologic effects of dronedarone (SR33589), a non-iodinated benzofuran derivative, in the rabbit heart: Comparison with amiodarone
98. Ks in guinea pig ventricular myocytes
99. Effects of dronedarone on calcium handling in cardiac ventricular myocytes
100. Electrophysiologic effects of long-term treatment with SR 33589 on rabbit atrial muscle. Comparison with amiodarone
101. Inhibitory effects of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells
102. Electrophysiological characterization of dronedarone (SR 33589), a new amiodarone-like agent, in cardiac ventricular myocytes
103. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats
104. The effect on cardiac muscle of two drugs, related to amiodarone, L8040 and L8462
105. Dose-dependent effects of dronedarone on the circadian patterns of RR and QT intervals in healthy subjects
106. What should we expect from the next generation of antiarrhythmic drugs?
107. Molecular aspects of arrhythmias associated with cardiomyopathies
108. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. International Consensus on Science